Your browser doesn't support javascript.
loading
Caregivers' attitudes toward blood-based biomarker testing for Alzheimer's disease.
Bolsewig, Katharina; Blok, Hester; Willemse, Eline A J; Zwaaftink, Rob B M Groot; Kooistra, Minke; Smets, Ellen M A; Teunissen, Charlotte E; Visser, Leonie N C.
Afiliación
  • Bolsewig K; Department of Laboratory Medicine Neurochemistry Laboratory Amsterdam Neuroscience Amsterdam UMC VU University Amsterdam the Netherlands.
  • Blok H; Alzheimer Nederland Amersfoort the Netherlands.
  • Willemse EAJ; Department of Laboratory Medicine Neurochemistry Laboratory Amsterdam Neuroscience Amsterdam UMC VU University Amsterdam the Netherlands.
  • Zwaaftink RBMG; Department of Neurology Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel Departments of Biomedicine and Clinical Research University Hospital Basel and University of Basel Basel Switzerland.
  • Kooistra M; Alzheimer Nederland Amersfoort the Netherlands.
  • Smets EMA; Alzheimer Nederland Amersfoort the Netherlands.
  • Teunissen CE; Department of Medical Psychology Amsterdam Public Health Research Institute University of Amsterdam Amsterdam UMC Amsterdam the Netherlands.
  • Visser LNC; Department of Laboratory Medicine Neurochemistry Laboratory Amsterdam Neuroscience Amsterdam UMC VU University Amsterdam the Netherlands.
Alzheimers Dement (Amst) ; 16(1): e12549, 2024.
Article en En | MEDLINE | ID: mdl-38371360
ABSTRACT

INTRODUCTION:

We aimed to evaluate informal caregivers' attitudes toward undergoing and future implementation of blood-based biomarkers (BBBM) testing for Alzheimer's disease (AD).

METHODS:

We explored caregivers' perspectives, by combining an online survey (n = 107) with a subsequent focus group (n = 7). We used descriptive statistics and thematic content analysis to identify common themes in answers to open-ended survey questions and focus group data.

RESULTS:

Most caregivers (72.0%) favored BBBM for AD diagnosis. Provided with hypothetical scenarios, confidence in a normal result decreased significantly if experienced symptoms were more severe (mild 78.5% vs. severe 48.6%). Caregivers' attitudes toward BBBM for screening purposes significantly improved with prospect of treatment (53.3% vs. 92.5%). Concerns toward BBBM testing included treatment unavailability, increased/prolonged distress, and AD-related stigma. Potential benefits were actionability, explanation for symptoms, and opportunities for better care and future treatment.

DISCUSSION:

Emerging AD treatment and reduction of AD-related stigma could profoundly increase public interest in BBBM testing for AD. Highlights Most informal caregivers would want blood-based biomarker (BBBM) testing for Alzheimer's disease (AD) diagnosis.Perceived (dis)advantages were related to diagnosing AD early.With severe symptoms, there was less confidence in normal BBBM results.Treatment availability would significantly increase interest in BBBM testing for AD.Informal caregivers showed uncertainty regarding the meaning of the term "AD."
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Alzheimers Dement (Amst) Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Alzheimers Dement (Amst) Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos